Relationship between lipoprotein(a) concentrations and intima-media thickness: A healthy population study

European Journal of Preventive Cardiology

Volumn 19, Issue 6, 2012, Pages 1290-1295

  Calmarza, P ^a   Trejo, J M ^b   Lapresta, C ^a   Lopez, P ^b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

Atherosclerotic plaques; cardiovascular risk; carotid artery; early arteriosclerosis; intima media thickness; lipoprotein(a); thrombosis

Indexed keywords

LIPOPROTEIN A;

ADULT; AGED; ANTHROPOMETRY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; B SCAN; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; COMMON CAROTID ARTERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PRIORITY JOURNAL; SPAIN;

EID: 84873922256     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711423216     Document Type: Article

References (32)

1. Touboul PJ, Labreuche J, Vicaut E, Amarenco P. Carotid intima-media thickness, plaques, and Framingham risk score as independent determinants of stroke risk. Stroke. 2005 ; 36 (8). 1741-1745
2. Masoura C, Pitsavos C, Aznaouridis K, Skoumas I, Vlachopoulos C, Stefanadis C. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis. 2011 ; 214 (1). 129-138
3. Van den Berg E, Biessels GJ, Stehouwer CD, Kappelle LJ, Heine RJ, Nijpels G, et al. Ten-year time course of risk factors for increased carotid intima-media thickness: the Hoorn Study. Eur J Cardiovasc Prev Rehabil. 2010 ; 17 (2). 168-174
4. Rasouli ML, Nasir K, Blumenthal RS, Park R, Aziz DC, Budoff MJ. Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis. 2005 ; 181 (1). 159-165
5. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 ; 330 (6144). 132-137
6. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 2004 ; 24 (12). 2219-2226
7. Marcovina SM, Albers JJ, Jacobs DR, Perkins LL, Lewis CE, Howard BV, et al. Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans. The CARDIA study. Arterioscler Thromb. 1993 ; 13 (7). 1037-1045
8. Miles LA, Fless GM, Scanu AM, Baynham P, Sebald MT, Skocir P, et al. Interaction of Lp(a) with plasminogen binding sites on cells. Thromb Haemost. 1995 ; 73 (3). 458-465
9. Kirschenlohr HL, Metcalfe JC, Weissberg PL, Grainger DJ. Proliferation of human aortic vascular smooth muscle cells in culture is modulated by active TGF beta. Cardiovasc Res. 1995 ; 29 (6). 848-855
10. Berg K. A new serum type system in man- the Lp system. Acta Pathol Microbiol Scand. 1963 ; 59: 369-382
11. Comisión de Lípidos y Lipoproteínas. Protocolo para la obtención de especimenes en las determinaciones de lípidos y lipoproteínas. Quím Clin. 1989 ; 8 (5). 349-361
12. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Couderc R, et al. Use of a reference material proposed by The International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000 ; 46 (12). 1956-1967
13. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986 ; 74 (4). 758-765
14. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ. 1990 ; 301 (6763). 1248-1251
15. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 1986 ; 62 (3). 249-257
16. Kitajima S, Jin Y, Koike T, Yu Y, Liu E, Shiomi M, et al. Lp(a) enhances coronary atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits. Atherosclerosis. 2007 ; 193 (2). 269-276
17. Baldassarre D, Tremoli E, Franceschini G, Michelagnoli S, Sirtori CR. Plasma lipoprotein (a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients. Stroke. 1996 ; 27 (6). 1044-1049
18. Fadini GP, Coracina A, Inchiostro S, Tiengo A, Avogaro A, de Kreutzenberg SV. A stepwise approach to assess the impact of clustering cardiometabolic risk factors on carotid intima-media thickness: the metabolic syndrome no-more-than-additive. Eur J Cardiovasc Prev Rehabil. 2008 ; 15 (2). 190-196
19. De Michele M, Iannuzzi A, Panico S, Celentano E, Sacchetti L, Mazzaccara C, et al. Effect of high-density lipoprotein cholesterol levels on carotid artery geometry in a Mediterranean female population. Eur J Cardiovasc Prev Rehabil. 2004 ; 11 (5). 403-407
20. Srámek A, Reiber JH, Baak-Pablo R, Sturk A, Rosendaal FR. Lipoprotein(a) and ultrasonographically determined early atherosclerotic changes in the carotid and femoral artery. J Thromb Haemost. 2003 ; 1 (2). 374-379
21. Denti L, Marchini L, Pasolini G, Baffoni MT, Ablondi F, Valenti G. Lipoprotein Lp(a) and cerebrovascular disease in the elderly: correlations with the severity of extracranial carotid atherosclerosis assessed by ultrasonography. Acta Biomed Ateneo Parmense. 1995 ; 66 (3-4). 175-183
22. Grebe MT, Schoene E, Schaefer CA, Boedeker RH, Kemkes-Matthes B, Voss R, et al. Elevated Lipoprotein (a) does not promote early atherosclerotic changes of the carotid arteries in young, healthy adults. Atherosclerosis. 2007 ; 190 (1). 194-198
23. El-Gendi SS, Bakeet MY, El-Hamed EA, Ibrahim FK, Ahmed R. The value of lipoprotein (a), homocysteine, and Doppler of carotid and femoral arteries in assessment of atherosclerosis in asymptomatic cardiovascular risk patients. J Cardiol. 2008 ; 52 (3). 202-211
24. Linnebank M, Moskau S, Farmand S, Fliessbach K, Kölsch H, Bös M, et al. Homocysteine and carotid intima-media thickness in a german population: lack of clinical relevance. Stroke. 2006 ; 37 (11). 2840-2842
25. Jones DW, Chambless LE, Folsom AR, Heiss G, Hutchinson RG, Sharrett AR, et al. Risk factors for coronary heart disease in African Americans: the atherosclerosis risk in communities study, 1987-1997. Arch Intern Med. 2002 ; 162 (22). 2565-2571
26. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R. Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 1996 ; 16 (3). 471-478
27. Emerging risk factors collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009 ; 302 (4). 412-423
28. Calmarza P, Cordero J, Santos V, Vella JC. Apolipoprotein(a) isoforms in infarcted men under 60 years old. Clin Biochem. 2004 ; 37 (10). 911-918
29. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009 ; 301 (22). 2331-2339
30. Liu L, Craig AW, Meldrum HD, Marcovina SM, Elliott BE, Koschinsky ML. Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3. Biochem J. 2009 ; 418 (2). 325-336
31. Cho T, Jung Y, Koschinsky ML. Apolipoprotein(a), through its strong lysine-binding site in KIV10, mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem. 2008 ; 283 (45). 30503-30512
32. Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, et al. MIRACL Study Investigators. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009 ; 53 (23). 2186-2196